Barbara Zeughauser had lost so many relatives to cancer: Her mother, her uncle, her grandmother, her second cousin. She thought that ghost in the family line might come after her, too. So in 2009, Zeughauser took a test offered by Myriad Genetics. It analyzed her DNA for mutations in the BRCA1 and BRCA2 genes that can make cancer more likely than not, raising the lifetime risk of breastcancer in women to between 55 and 85 percent, and to between 10 and 70 percent for ovariancancer.
Zeughauser was lucky and unlucky. She got a clear, unambiguous, and accurate answer from the test: She had a bad mutation. But she’d found it before she got cancer. She decided to have her ovaries removed and later had a double mastectomy, reducing her risk to almost average.
Her cousin Ken Deutsch wasn’t so lucky. In 2014, he was hit with bladder cancer. He also went...
MUMBRA, India — The afternoon sun shines on the woman in a commuter-town café, highlighting her almond-shaped eyes and pale skin, a look often sought after by couples who need an egg to have a baby.
By Roni Caryn Rabin, The New York Times | 01.22.2026
Aggregated News
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.
